Discovery of carmegliptin: A potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 3, 2010, Pages 1109-1113

  Mattei, Patrizio ^a   Boehringer, Markus ^a   Di Giorgio, Patrick ^a   Fischer, Holger ^a   Hennig, Michael ^a   Huwyler, Joerg ^a   Koçer, Buelent ^a   Kuhn, Bernd ^a   Loeffler, Bernd M ^a   MacDonald, Alexander ^a   Narquizian, Robert ^a   Rauber, Etienne ^a   Sebokova, Elena ^a   Sprecher, Urs ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Dipeptidyl peptidase IV; Glucagon like peptide 1; Structure based drug design

Indexed keywords

ANTIDIABETIC AGENT; CARMEGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; UNCLASSIFIED DRUG; DELAYED RELEASE FORMULATION; DIPEPTIDYL PEPTIDASE IV; DPP4 PROTEIN, HUMAN; QUINOLIZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG EFFICACY; DRUG EXCRETION; DRUG SYNTHESIS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; RAT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; ANIMAL; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DIABETES MELLITUS, TYPE 2; DOG; ENZYMOLOGY; HUMAN; MACACA FASCICULARIS; METABOLISM; PHASE 2 CLINICAL TRIAL (TOPIC); SYNTHESIS; WISTAR RAT; X RAY CRYSTALLOGRAPHY; ZUCKER RAT;

ANIMALIA;

ANIMALS; CLINICAL TRIALS, PHASE II AS TOPIC; CRYSTALLOGRAPHY, X-RAY; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOGS; DRUG DESIGN; HUMANS; HYPOGLYCEMIC AGENTS; MACACA FASCICULARIS; MICE; QUINOLIZINES; RATS; RATS, WISTAR; RATS, ZUCKER;

EID: 74049162952     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.12.024     Document Type: Article

References (30)

1. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., and Zinman B. Diabetes Care 32 (2009) 193
2. DeFronzo R.A. Diabetes 58 (2009) 773
3. Villhauer E.B., Coppola G.M., and Hughes T.E. Annu. Rep. Med. Chem. 36 (2001) 191
4. Drucker D.J., and Nauck M.A. Lancet 368 (2006) 1696
5. Ahrén B. Expert Opin. Emerg. Drugs 13 (2008) 593
6. Pei Z. Curr. Opin. Drug Discov. Devel. 11 (2008) 512
7. Gwaltney II S.L. Curr. Top. Med. Chem. 8 (2008) 1545
8. Boehringer, M.; et al. Bioorg. Med. Chem. Lett. 2009. doi:10.1016/j.bmcl.2009.12.025.
9. Rasmussen H.B., Branner S., Wiberg F.C., and Wagtmann N. Nat. Struct. Biol. 10 (2003) 19
10. Peters J.-U., Weber S., Kritter S., Weiss P., Wallier A., Boehringer M., Hennig M., Kuhn B., and Loeffler B.-M. Bioorg. Med. Chem. Lett. 14 (2004) 1491
11. Virtual screening was performed in the following way: (a) selection of 2273 potential building blocks with MW <200 from the Available Chemicals Directory (ACD) and the Roche compound depository; (b) enumeration of a virtual library of aminobenzo[a]quinolizines with MOE (http://www.chemcomp.com/); (c) FlexX/Screenscore (Version 1.13.5, http://www.biosolveit.de/FlexX/) docking into the binding site of DPP-IV (PDBid: 3kwh) using the ring scaffold of the HTS hit 1 as base fragment reference (option SELBAS=reference) and a slightly increased tolerance for protein-ligand overlap (option MAX_OVERLAP_VOL=3.5); (d) visual inspection, filtering, and refinement of top 150 hits in Moloc (Gerber, P. R.; Mueller, K. J. Comput. Aided Mol. Des. 1995, 9, 251).
12. Boehringer, M.; Kuhn, B.; Mattei, P.; Narquizian, R. US Pat. Appl. 2004/0259903, 2004.
13. Brossi A., Lindlar H., Walter M., and Schnider O. Helv. Chim. Acta 41 (1958) 119
14. Gribble G.W. Chem. Soc. Rev. 27 (1998) 395
15. Ninomiya K., Shioiri T., and Yamada S. Tetrahedron 30 (1974) 2151
16. Lüllmann-Rauch R., Pods R., and von Witzendorff B. Toxicology 110 (1996) 27
17. Fischer, H.; Kansy, M.; Potthast, M.; Csato, M. Rational Approaches to Drug Design, Proceedings of the European Symposium on Quantitative Structure-Activity Relationships, 13th, Düsseldorf, Germany, Aug 27-Sept 1, 2000, p 286.
18. Hamill O.P., Marty A., Neher E., Sakmann B., and Sigworth F.J. Pflügers Arch. 391 (1981) 85
19. Crawforth J.M., Fawcett J., and Rawlings B.J. J. Chem. Soc., Perkin Trans. 1 (1998) 1721
20. Mori K., and Yamane K. Tetrahedron 38 (1982) 2919
21. Lal G.S., Pez G.P., Pesaresi R.J., Prozonic F.M., and Chen H. J. Org. Chem. 64 (1999) 7048
22. The coordinates of the X-ray complex structure of human DPP-IV with compound 8p have been deposited at the Protein Data Bank, accession code 3kwf.
23. Pospisilik J.A., Stafford S.G., Demuth H.-U., McIntosh C.H.S., and Pederson R.A. Diabetes 51 (2002) 2677
24. Selectivity screenings were performed at Cerep S. A., Celle l'Evescault, France.
25. Van der Veken P., Haemers A., and Augustyns K. Curr. Top. Med. Chem. 7 (2007) 621
26. Kirby M., Yu D.M.T., O'Connor S., and Gorrell M.D. Clin. Sci. 118 (2010) 31
27. Lübbers T., Böhringer M., Gobbi L., Hennig M., Hunziker D., Kuhn B., Löffler B., Mattei P., Narquizian R., Peters J.-U., Ruff Y., Wessel H.P., and Wyss P. Bioorg. Med. Chem. Lett. 17 (2007) 2966
28. Kansy M., Senner F., and Gubernator K. J. Med. Chem. 41 (1998) 1007
29. Bendels S., Kansy M., Wagner B., and Huwyler J. Eur. J. Med. Chem. 43 (2008) 1581
30. Fischer H., Kansy M., and Bur D. Chimia 54 (2000) 640